Phosphoglycerate mutase regulates Treg differentiation through control of serine synthesis and one-carbon metabolism

Reviewer #1 (Public review):

Summary:

This work provides a new potential tool to manipulate Tregs function for therapeutic use. It focuses on the role of PGAM in Tregs differentiation and function. The authors, interrogating publicly available transcriptomic and proteomic data of human regulatory T cells and CD4 T cells, state that Tregs express higher levels of PGAM (at both message and protein levels) compared to CD4 T cells. They then inhibit PGAM by using a known inhibitor ECGC and show that this inhibition affects Tregs differentiation. This result was also observed when they used antisense oligonucleotides (ASOs) to knockdown PGAM1.

PGAM1 catalyzes the conversion of 3PG to 2PG in the glycolysis cascade. However, the authors focused their attention on the additional role of 3PG: acting as starting material for the de novo synthesis of serine.

They hypothesized that PGAM1 regulates Tregs differentiation by regulating the levels of 3PG that are available for de novo synthesis of serine, which has a negative impact on Tregs differentiation. Indeed, they tested whether the effect on Tregs differentiation observed by reducing PGAM1 levels was reverted by inhibiting the enzyme that catalyzes the synthesis of serine from 3PG.

The authors continued by testing whether both synthesized and exogenous serine affect Tregs differentiation and continued with in vivo experiments to examine the effects of dietary serine restriction on Tregs function.

In order to understand the mechanism by which serine impacts Tregs function, the authors assessed whether this depends on the contribution of serine to one-carbon metabolism and to DNA methylation.

The authors therefore propose that extracellular serine and serine whose synthesis is regulated by PGAM1 induce methylation of genes Tregs associated, downregulating their expression and overall impacting Tregs differentiation and suppressive functions.

Strengths:

The strength of this paper is the number of approaches taken by the authors to verify their hypothesis. Indeed, by using both pharmacological and genetic tools in in vitro and in vivo systems they identified a potential new metabolic regulation of Tregs differentiation and function.

Weaknesses:

Using publicly available transcriptomic and proteomic data of human T cells, the authors claim that both ex vivo and in vitro polarized Tregs express higher levels of PGAM1 protein compared to CD4 T cells (naïve or cultured under Th0 polarizing conditions). The experiments shown in this paper have all been carried out in murine Tregs. Publicly available resources for murine data (ImmGen -RNAseq and ImmPRes - Proteomics) however show that Tregs do not express higher PGAM1 (mRNA and protein) compared to CD4 T cells. It would be good to verify this in the system/condition used in the paper.

It would also be good to assess the levels of both PGAM1 mRNA and protein in Tregs PGAM1 knockdown compared to scramble using different methods e.g. qPCR and western blot. However, due to the high levels of cell death and differentiation variability, that would require cells to be sorted.

It is not specified anywhere in the paper whether cells were sorted for bulk experiments. Based on the variability of cell differentiation, it would be good if this was mentioned in the paper as it could help to interpret the data with a different perspective.

Reviewer #2 (Public review):

Summary:

The authors have tried to determine the regulatory role of Phosphoglycerate mutate (PGAM), an enzyme involved in converting 3-phosphoglycerate to 2-phosphoglycerate in glycolysis, in differentiation and suppressive function of regulatory CD4 T cells through de novo serine synthesis. This is done by contributing one carbon metabolism and eventually epigenetic regulation of Treg differentiation.

Strengths:

The authors have rigorously used inhibitors and antisense RNA to verify the contribution of these pathways in Treg differentiation in-vitro. This has also been verified in an in-vivo murine model of autoimmune colitis. This has further clinical implications in autoimmune disorders and cancer.

Weaknesses:

The authors have used inhibitors to study pathways involved in Treg differentiation. However, they have not studied the context of overexpression of PGAM, which was the actual reason to pursue this study.